1. Endo thinks it has the financial flexibility to weather the storm of opioid settlements — Takeda acquires celiac-focused PvP Biologics — Iovance jumps on buyout rumors — See more on our front page news TRY TWO WEEKS OF OUR EMAIL NEWS HEADLINES FOR FREE
    Dismiss Notice
  2. Think you have witnessed fraud?Ask a Whistleblower Attorney -- a chance to discuss whistleblower-related legal issues with practicing whistleblower attorneys.
    Dismiss Notice


Discussion in 'Bayer' started by Jon S, Oct 1, 2019 at 8:30 AM.

Tags: Add Tags
  1. Jon S

    Jon S Guest

    What is Bayer doing lately to try to get the stock price up? Any thoughts on spinning off women’s health to Abbvie, Cooper surgical or Hologic?
    Any thoughts on the oncology franchise?
    Any hope for the stock or is it doomed?

  2. anonymous

    anonymous Guest

    sell, sell, sell (& I’m not talking about the reps)
  3. anonymous

    anonymous Guest

    oncology is subpar but it’s the only thing Bayer has going for it in the pharma space. The only long term hope is divestiture. Keep agro science as a stand only company. Sell pharma & OTC to get stock price back in the $20’s. This is still a far cry from the days of $35+ prior to the purchase of Monsanto. Bayer is being taught in MBA programs on what not to do
  4. anonymous

    anonymous Guest

    How about rename the company? Any suggestions?
  5. anonymous

    anonymous Guest